Lexicon to disband sales team, lay off 60% of staff

Lexicon to disband sales team, lay off 60% of staff

Source: 
BioPharma Dive
snippet: 

The restructuring follows the company’s receipt of a letter from the FDA citing “deficiencies” in its approval application for diabetes drug Zynquista.